Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 2.4
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Kobo Biotech Ltd. engages in the business of pharmaceuticals products. It focuses on manufacturing active pharmaceutical ingredients (API) based on fermentation technology. The company was founded on August 3, 1992 and is headquartered in Mumbai, India.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overpriced on P/FCF.
Data is available to registered users only
Buy
Sell